Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis
Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis
复制标题
DOI：
10.1002/ibd.20112
复制
发表时间：
2007-07
影响因子：
4.9
通讯作者：
S. Yoshizawa;K. Matsuoka;N. Inoue;H. Takaishi;H. Ogata;Y. Iwao;M. Mukai;T. Fujita;Y. Kawakami;T. Hibi
中科院分区：
文献类型：
--
作者：
S. Yoshizawa;K. Matsuoka;N. Inoue;H. Takaishi;H. Ogata;Y. Iwao;M. Mukai;T. Fujita;Y. Kawakami;T. Hibi
背景资料：为了早期发现溃疡性结肠炎（UC）相关的结直肠癌（CRC），建议在高危UC患者中进行监测性结肠镜检查。然而，较差的可接受性恶化了其有效性，需要一个合适的标记来选择高风险患者。在此，我们使用UC患者的血清样本，评价了通过酶联免疫吸附试验（ELISA）测量抗p53抗体（Ab）的临床实用性。方法：收集286例UC患者、82例散发性CRC患者和63例健康对照者的血清。用ELISA检测血清抗p53抗体。免疫组化检测也进行了谁开发异型增生或CRC患者。结果：p53 Ab在UC中的阳性率为15.0%，在HC中的阳性率为1.6%。散发性CRC中阳性率为52.4%。病程≥ 8年的UC患者血清p53 Ab阳性率明显高于病程较短者。13例UC伴结直肠癌或异型增生患者中8例（61.5%）p53抗体阳性，显著高于无肿瘤者。所有UC伴结直肠癌患者p53染色均阳性，2例血清p53 Ab阴性。最后，我们可以在手术后监测4例CRC患者的血清p53 Ab水平下降。结论：这项研究显示，p53 Ab在UC相关CRC的进展中产生，但并非在所有肿瘤患者中产生，这表明通过ELISA进行p53 Ab的血清学检测不适合主要选择高风险患者;但是，它有助于挽救从监测计划中脱落的患者。（炎症性肠病，2007年）
Background: For early detection of ulcerative colitis (UC)‐associated colorectal cancer (CRC), surveillance colonoscopy is recommended in UC patients at high risk. However, poor acceptability deteriorates its effectiveness and a suitable marker for selecting patients at high risk is needed. Here we evaluated clinical usefulness of the measurement of anti‐p53 antibodies (Abs) by enzyme‐linked immunosorbent assay (ELISA) using sera samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with sporadic CRC, and 63 healthy controls (HC) were obtained. Serum anti‐p53 antibodies were detected with ELISA. Immunohistochemical detection was also performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive in 15.0% of UC, while it was positive only in 1.6% of HCs. In sporadic CRCs, 52.4% of 82 patients were positive. In UC patients with disease duration equal to or longer than 8 years, positivity of serum p53 Ab was significantly higher than those in patients with shorter duration. Eight of 13 (61.5%) UC patients with CRC or dysplasia were positive for serum p53 Abs, which was significantly higher than that in patients without neoplasia. All UC patients with CRC were positive for p53 staining, while 2 were negative for serum p53 Ab. Finally, levels of serum p53 Ab had fallen in 4 patients with CRC we could monitor after surgery. Conclusions: This study revealed that p53 Ab developed in the progression of UC‐associated CRC but not in all patients with neoplasia, suggesting that serological detection of p53 Abs by ELISA is not suitable in primarily selecting patients at high risk; however, it is helpful in salvaging patients who drop from a surveillance program. (Inflamm Bowel Dis 2007)